Business
Degenerative Disc Patients Significantly Improve with USRM’s AdipocellTM
Degenerative Disc Patients Significantly Improve with USRM’s AdipocellTM.
About this update from U.s. Stem Cell, Inc.
[{"type":"text","content":"\n \n U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of \n proprietary, physician-based stem cell therapies and novel regenerative \n medicine solutions, today announced Chief Science Officer Dr. Kristin \n Comella will present clinical data demonstrating safety and efficacy of \n its proprietary AdipocellTM therapy in treating \n degenerative disc disease — a condition that affects more than 65 \n million Americans annually1 — at the Annual \n Meeting for International Federation for Adipose Therapeutics and \n Science (IFATS).\n \n \n Dr. Comella, who is a global leader in the development of revolutionary \n holistic stem cell therapies, will discuss her paper “Effects \n of the Intradiscal Implantation of Stromal Vascular Fraction Plus \n Platelet Rich Plasma in Patients With Degenerative Disc Disease,” \n on Thursday, November 30, 5:30 p.m., at the Lowes Hotel Miami Beach. Dr. \n Comella’s presentation will also be live streamed at www.facebook.com/comella.stem.cell/.\n \n \n The study, which included 15 patients with degenerative disc disease, \n featured the use of USRM’s proprietary AdipocellTM therapy \n following a local tumescent liposuction procedure to remove \n approximately 60 ml of fat tissue. AdipocellTM kits and \n enzyme were used to separate and isolate a patient’s \n own stromal vascular fraction (SVF) which was then delivered into \n the disc of patients.\n \n \n Patients were then monitored for 6 months for adverse events, range of \n motion, visual analog scale (VAS), present pain intensity (PPI), \n Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), Dallas \n Pain Questionnaire and Short Form (SF)-12 scores. Safety events were \n also monitored, for a 12-month period.\n \n \n The procedure demonstrated a strong safety profile with no severe \n adverse events (SAEs) or complications linked to the therapy they \n received, and no incidences of infection. Patients who participated in \n this study experienced statistically significant improvements in several \n parameters including flexion, pain ratings, VAS, PPI, and short form \n questionnaires. In addition, both ODI and BDI data was trending positive \n and a majority of patients reported improvements in their Dallas Pain \n Questionnaire scores. More importantly, patients o...